No matches

Educational Resources

Both Clinical and Subclinical Disease Control Are Important to Achieve Disease Modification in AD

Which Biomarkers of AD Might Be Robust Enough to Be Evaluated as a Measure of Disease Modification?

Dermatology

4 min

expert video

Which Biomarkers of AD Might Be Robust Enough to Be Evaluated as a Measure of Disease Modification?

Atopic Dermatitis and the Growing Evidence for Its Association with Various Non-Atopic Systemic Diseases

Dermatology

2 min

expert video

Atopic Dermatitis and the Growing Evidence for Its Association with Various Non-Atopic Systemic Diseases

Atopic Dermatitis and the Risk of Developing Other Atopic Diseases

Dermatology

3 min

expert video

Atopic Dermatitis and the Risk of Developing Other Atopic Diseases

Atopic and Nonatopic Comorbidities in AD and the Importance of Early Intervention

Dermatology

5 min

expert video

Atopic and Nonatopic Comorbidities in AD and the Importance of Early Intervention

Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch

Dermatology

4 min

expert video

Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch

How Biologic Therapy May Lead to Disease Modification in Infants and Children With Atopic Dermatitis

Dermatology

46 min

expert video

How Biologic Therapy May Lead to Disease Modification in Infants and Children With Atopic Dermatitis

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

Dermatology

10 min

expert video

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: South AfricaChange country/region